Abstract Library

#4189 Pit and pitfalls of tumor mutational burden assessment in well-differentiated pancreatic neuroendocrine tumors: Two case reports from University of Verona

Introduction: The hypermutated phenotype is used as a predictive parameter for immune-checkpoint inhibitors (ICI). However, the relationship between high TMB, the underlying mutational drivers and response to ICI is still unclear.

Conference:

Presenting Author: Trevisani E

Authors: Torresan I, Reni A, Trevisani E, Borghesani M, Rossi A,

Keywords: Neuroendocrine tumor, NGS, Tumor Mutational Burden, Alkylating agent, DNA Damage Repair, Liquid biopsy,

#4182 DNA damage repair genes alterations in pancreatic neuroendocrine tumor treated with Temozolomide

Introduction: Temozolomide (TMZ), a standard therapy for pancreatic neuroendocrine tumors (pNETs), is an alkylating agent causing missense mutations and triggering cell death.

Conference:

Presenting Author: Trevisani E

Authors: Trevisani E, Reni A, Torresan I, Borghesani M, Rossi A,

Keywords: DNA Damage Repair, Tumor mutational burden, Neuroendocrine, Temozolomide,

#3891 Exceptional response to Everolimus in a pancreatic NET G3 (pNET) – How NGS can help in treatment choice

Introduction: Exceptional Responders are defined as patients who achieve complete (CR) or partial response (PR) for at least 6 months to a treatment with population PR or CR rate less than 10%, or patients with CR or PR lasting more than three times the median duration of response.

Conference:

Presenting Author: Torresan I

Authors: Torresan I, Mafficini A, Benini L, Borghesani M, Moscarda V,

Keywords: pNET, NGS, G3, everolimus, TSC2,

#3860 NGS data collection in high-grade (HG) pancreatic NENs at University Hospital of Verona

Introduction: Molecular data for G3 pancreatic neuroendocrine neoplasms (pNEN) are limited. G3 category includes well-differentiated NET G3 and NEC. The biology and clinical behaviour of NET G3 are different from NEC.

Conference:

Presenting Author: Rossi A

Authors: Rossi A, Cingarlini S, Borghesani M, Moscarda V, Torresan I,

Keywords: NGS, pNEN, G3, precision medicine,

#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: González Devia D

Authors: Guzman Ruiz Y, Vera Torres A, López Panqueva R, Ardila Duarte G, González Devia D,

Keywords: Pancreatic neuroendocrine tumors, Pancreatic tumor, Prognosis, Neuroendocrine tumor, Gastroenteropancreatic tumor,